177 related articles for article (PubMed ID: 23965133)
1. Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment.
Hirvinen M; Heiskanen R; Oksanen M; Pesonen S; Liikanen I; Joensuu T; Kanerva A; Cerullo V; Hemminki A
J Transl Med; 2013 Aug; 11():193. PubMed ID: 23965133
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility to
Fall AKDJ; Dechavanne C; Sabbagh A; Guitard E; Milet J; Garcia A; Dugoujon JM; Courtin D; Migot-Nabias F
Front Immunol; 2020; 11():608016. PubMed ID: 33424858
[TBL] [Abstract][Full Text] [Related]
3. FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.
Erbe AK; Wang W; Goldberg J; Gallenberger M; Kim K; Carmichael L; Hess D; Mendonca EA; Song Y; Hank JA; Cheng SC; Signoretti S; Atkins M; Carlson A; Mier JW; Panka DJ; McDermott DF; Sondel PM
Clin Cancer Res; 2017 May; 23(9):2159-2168. PubMed ID: 27742794
[No Abstract] [Full Text] [Related]
4. Fc-Gamma receptor polymorphism and gene expression of peripheral blood mononuclear cells in patients with HER2-positive metastatic breast cancer receiving single-agent trastuzumab.
Shimizu C; Mogushi K; Morioka MS; Yamamoto H; Tamura K; Fujiwara Y; Tanaka H
Breast Cancer; 2016 Jul; 23(4):624-32. PubMed ID: 25962696
[TBL] [Abstract][Full Text] [Related]
5. Fragment c gamma receptor gene polymorphisms and breast cancer risk in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians.
Iwasaki M; Shimada N; Kasuga Y; Yokoyama S; Onuma H; Nishimura H; Kusama R; Hamada GS; Nishimoto IN; Iyeyasu H; Motola J; Laginha FM; Anzai R; Tsugane S
Breast Cancer Res Treat; 2011 Apr; 126(2):497-505. PubMed ID: 20697800
[TBL] [Abstract][Full Text] [Related]
6. Role of Fcgamma receptors IIA, IIIA, and IIIB in susceptibility to rheumatoid arthritis.
Radstake TR; Petit E; Pierlot C; van de Putte LB; Cornelis F; Barrera P
J Rheumatol; 2003 May; 30(5):926-33. PubMed ID: 12734884
[TBL] [Abstract][Full Text] [Related]
7. Effect of FCGR2A and FCGR3A variants on CLL outcome.
Dornan D; Spleiss O; Yeh RF; Duchateau-Nguyen G; Dufour A; Zhi J; Robak T; Moiseev SI; Dmoszynska A; Solal-Celigny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Rossiev VA; Bence-Bruckler I; Geisler CH; Montillo M; Wenger MK; Weisser M
Blood; 2010 Nov; 116(20):4212-22. PubMed ID: 20705761
[TBL] [Abstract][Full Text] [Related]
8. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.
Persky DO; Dornan D; Goldman BH; Braziel RM; Fisher RI; Leblanc M; Maloney DG; Press OW; Miller TP; Rimsza LM
Haematologica; 2012 Jun; 97(6):937-42. PubMed ID: 22271896
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
Musolino A; Naldi N; Bortesi B; Pezzuolo D; Capelletti M; Missale G; Laccabue D; Zerbini A; Camisa R; Bisagni G; Neri TM; Ardizzoni A
J Clin Oncol; 2008 Apr; 26(11):1789-96. PubMed ID: 18347005
[TBL] [Abstract][Full Text] [Related]
10. FCGR3A and FCGR2A Genotypes Differentially Impact Allograft Rejection and Patients' Survival After Lung Transplant.
Paul P; Pedini P; Lyonnet L; Di Cristofaro J; Loundou A; Pelardy M; Basire A; Dignat-George F; Chiaroni J; Thomas P; Reynaud-Gaubert M; Picard C
Front Immunol; 2019; 10():1208. PubMed ID: 31249568
[TBL] [Abstract][Full Text] [Related]
11. Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab.
Ajeganova S; Tesfa D; Hägglund H; Fadeel B; Vedin I; Zignego AL; Palmblad J
Arthritis Res Ther; 2017 Mar; 19(1):44. PubMed ID: 28270182
[TBL] [Abstract][Full Text] [Related]
12. FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.
Geva R; Vecchione L; Kalogeras KT; Jensen BV; Lenz HJ; Yoshino T; Paez D; Montagut C; Souglakos J; Cappuzzo F; Cervantes A; Frattini M; Fountzilas G; Johansen JS; Høgdall EV; Zhang W; Yang D; Yamazaki K; Nishina T; Papamichael D; Vincenzi B; Macarulla T; Loupakis F; De Schutter J; Spindler KL; Pfeiffer P; Ciardiello F; Piessevaux H; Tejpar S
Gut; 2015 Jun; 64(6):921-8. PubMed ID: 25011934
[TBL] [Abstract][Full Text] [Related]
13. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
[TBL] [Abstract][Full Text] [Related]
14. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
Zhang W; Gordon M; Schultheis AM; Yang DY; Nagashima F; Azuma M; Chang HM; Borucka E; Lurje G; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
J Clin Oncol; 2007 Aug; 25(24):3712-8. PubMed ID: 17704420
[TBL] [Abstract][Full Text] [Related]
15. Functional polymorphisms of PTPN22 and FcgR genes in Tunisian patients with rheumatoid arthritis.
Sfar I; Dhaouadi T; Habibi I; Abdelmoula L; Makhlouf M; Ben Romdhane T; Jendoubi-Ayed S; Aouadi H; Ben Abdallah T; Ayed K; Zouari R; Lakhoua-Gorgi Y
Arch Inst Pasteur Tunis; 2009; 86(1-4):51-62. PubMed ID: 20707220
[TBL] [Abstract][Full Text] [Related]
16. FcγRIIIa receptor polymorphism influences NK cell mediated ADCC activity against HIV.
Talathi SP; Shaikh NN; Pandey SS; Saxena VA; Mamulwar MS; Thakar MR
BMC Infect Dis; 2019 Dec; 19(1):1053. PubMed ID: 31842762
[TBL] [Abstract][Full Text] [Related]
17. Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia.
Burkhardt B; Yavuz D; Zimmermann M; Schieferstein J; Kabickova E; Attarbaschi A; Lisfeld J; Reiter A; Makarova O; Worch J; Bonn BR; Damm-Welk C
Ann Hematol; 2016 Sep; 95(9):1503-12. PubMed ID: 27376362
[TBL] [Abstract][Full Text] [Related]
18. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.
Kanerva A; Nokisalmi P; Diaconu I; Koski A; Cerullo V; Liikanen I; Tähtinen S; Oksanen M; Heiskanen R; Pesonen S; Joensuu T; Alanko T; Partanen K; Laasonen L; Kairemo K; Pesonen S; Kangasniemi L; Hemminki A
Clin Cancer Res; 2013 May; 19(10):2734-44. PubMed ID: 23493351
[TBL] [Abstract][Full Text] [Related]
19. Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.
Shepshelovich D; Townsend AR; Espin-Garcia O; Latifovic L; O'Callaghan CJ; Jonker DJ; Tu D; Chen E; Morgen E; Price TJ; Shapiro J; Siu LL; Kubo M; Dobrovic A; Ratain MJ; Xu W; Mushiroda T; Liu G
Cancer Med; 2018 Nov; 7(11):5478-5487. PubMed ID: 30318772
[TBL] [Abstract][Full Text] [Related]
20. Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus.
Taipale K; Liikanen I; Juhila J; Turkki R; Tähtinen S; Kankainen M; Vassilev L; Ristimäki A; Koski A; Kanerva A; Diaconu I; Cerullo V; Vähä-Koskela M; Oksanen M; Linder N; Joensuu T; Lundin J; Hemminki A
Mol Ther; 2016 Feb; 24(1):175-83. PubMed ID: 26310629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
